TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29997249
Drug: Low-dose mTOR
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mTOR inhibitor therapy (combination of BEZ235 and RAD001)
Study: 22383266
Drug: Bergamot essential
Normalized name: Nature's Truth Bergamot Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bergamot essential oil inhalation
Study: 15877554
Drug: NITE-AD intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: NITE-AD intervention (sleep hygiene education, daily walking, increased light exposure)
Study: 12700935
Drug: Manipulation under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manipulation under anaesthesia (MUA) with intra-articular normal saline injection
Study: 12700935
Drug: Manipulation under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manipulation under anaesthesia (MUA) with intra-articular methylprednisolone injection
Study: 10472779
Drug: MPA (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (medroxyprogesterone acetate) at a daily total dose of 500 mg
Study: 8758107
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg, Isoniazid 400 mg, and Pyrazinamide 1.25 g daily for 3 months
Study: 1765317
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nalbuphine
Study: 1451900
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pethidine
Study: 6751144
Drug: Intramuscular regime
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular regime
Study: 30450637
Drug: 3K3A-APC at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3K3A-APC at 540 μg/kg
Study: 26477023
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy and relaxation treatment (SHE treatment)
Study: 23639598
Drug: RM-131 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM-131 (100 μg, subcutaneously)
Study: 19116919
Drug: Resolved CIL
Normalized name: penicillin V potassium Oral Capsule [V-Cil-K]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resolved CIL after anti-TNF treatment
Study: 11212971
Drug: Mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50 mg daily for 2 weeks, then 100 mg daily for 4 weeks
Study: 11212971
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg daily for 2 weeks, then 60 mg daily for 4 weeks
Study: 8086844
Drug: Workshop on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workshop on medical ethics for family medicine preceptors
Study: 25011982
Drug: Flutamide treatment
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide treatment (GD50F)
Study: 25011982
Drug: Flutamide treatment
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide treatment (GD90F)
Study: 25011982
Drug: Flutamide treatment
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide treatment (GD108F)
Study: 22236137
Drug: olanzapine-LAI 210
Normalized name: olanzapine 210 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine-LAI 210 mg/2 weeks
Study: 22236137
Drug: olanzapine-LAI 300
Normalized name: olanzapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine-LAI 300 mg/2 weeks
Study: 22236137
Drug: olanzapine-LAI 405
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine-LAI 405 mg/4 weeks
Study: 9141002
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine 40 micrograms
Study: 9141002
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine 20 micrograms
Study: 9141002
Drug: rHuIL‐2 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL‐2 administration (500,000 U)
Study: 31647032
Drug: Fast-track multidisciplinary
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track multidisciplinary treatment (FTMDT) with fast-track perioperative treatment and XELOX adjuvant chemotherapy
Study: 31647032
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with conventional perioperative treatment and mFOLFOX6 adjuvant chemotherapy
Study: 25643024
Drug: Adults discounting
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults discounting cannabis over treatment
Study: 25643024
Drug: Adolescents discounting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescents discounting cannabis over treatment
Study: 19828211
Drug: Pramiconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiconazole (200 mg taken once, and 200 mg taken once daily for 2 or 3 days)
Study: 17093160
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 5.8 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Study: 17093160
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 7.3 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Study: 17093160
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 12.9 mg . kg(‐1) . d(‐1) without dietary cysteine
Study: 17093160
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 17.2 mg . kg(‐1) . d(‐1) without dietary cysteine
Study: 15897725
Drug: intensive psychosocial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive psychosocial relapse‐prevention program + anxiety treatment program (CBT + optional SSRI)
Study: 9663809
Drug: L-N(G)-monomethyl-arginine (L-NMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-N(G)-monomethyl-arginine (L-NMMA) infusion
Study: 7831064
Drug: Defibrotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (400 mg tablet bid)
Study: 7831064
Drug: Mesoglycan (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan (24 mg tablet bid)
Study: 3343933
Drug: APM-sweetened beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: APM-sweetened beverage (10 mg APM/kg body weight per serving)
Study: 24498810
Drug: Hyoscine‐N‐butylbromide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine‐N‐butylbromide 40 mg intravenously
Study: 9324175
Drug: Atropine 0.5
Normalized name: homatropine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.5 mg intravenously
Study: 21258894
Drug: Chinese drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drugs for supporting essence and strengthening Pi (SESP)
Study: 21258894
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy + SESP
Study: 19692062
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia with a loading dose of 0.25% bupivacaine or 0.2% ropivacaine, followed by continuous drip 0.2% ropivacaine
Study: 19692062
Drug: Nonepidural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonepidural analgesia with intraoperative morphine and postoperative oxycodone or tramadol plus ibuprofen or paracetamol for 48 hours
Study: 17005508
Drug: No inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhaled anaesthetics
Study: 9239455
Drug: Granular formulation
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular formulation of lornoxicam (8 mg)
Study: 9239455
Drug: Standard tablets
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablets of lornoxicam (8 mg)
Study: 8513660
Drug: Computerized pharmacokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized pharmacokinetic program for adjusting theophylline infusion rates
Study: 29899015
Drug: Incentive arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incentive arm with personalized step goals and daily feedback for 24 weeks
Study: 26519995
Drug: Adjustable intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable intravenous loop diuretics (ALD)
Study: 10449884
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with thrombolytic treatment
Study: 10449884
Drug: Aspirin without
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin without thrombolytic treatment
Study: 1688487
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of AOAA four times a day for 1 week
Study: 318978
Drug: Amoxycillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (500 mg, three times a day for 10 days)
Study: 318978
Drug: Co-trimoxazole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (up to 480 mg trimethoprim and 2,400 mg sulphamethoxazole daily for males, two thirds of this dose for females)
Study: 28797783
Drug: tbo-filgrastim (Granix)
Normalized name: tbo-filgrastim Injection [Granix]
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tbo-filgrastim (Granix) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Study: 28797783
Drug: filgrastim (Neupogen)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: filgrastim (Neupogen) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Study: 20381664
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (first prescriptions)
Study: 20381664
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (second prescriptions)
Study: 12056785
Drug: 20% alanyl-glutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% alanyl-glutamine infusion of 0.5 g/kg
Study: 1730080
Drug: A +
Normalized name: Vital E- A + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A + I (cytarabine 100 mg/m2/d + idarubicin 13 mg/m2/d)
Study: 1730080
Drug: A +
Normalized name: Vital E- A + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A + D (cytarabine 100 mg/m2/d + daunorubicin 45 mg/m2/d)
Study: 6085363
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg)
Study: 3158125
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nifedipine and Acebutolol
Study: 27331824
Drug: l-leucine (LEU)
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-leucine (LEU)
Study: 21432578
Drug: manualized cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: manualized cognitive-behavioural group psychotherapy plus open methylphenidate treatment
Study: 17458426
Drug: Topical cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cetirizine dinitrate (4.4 mg twice daily)
Study: 17458426
Drug: Oral cetirizine
Normalized name: cetirizine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cetirizine dihydrochloride (10 mg once daily)
Study: 14694177
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine (CsA) and sirolimus (SRL); group 1
Study: 14694177
Drug: Full-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose cyclosporine (CsA) and mycophenolate mofetil; group 2
Study: 11215542
Drug: Standard after-care
Normalized name: DIMETHICONE 4 mg in 1 mL TOPICAL CREAM [AFTER CARE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard after-care treatment (comparison group)
Study: 25407559
Drug: O(6)-benzylguanine (O(6)-BG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O(6)-benzylguanine (O(6)-BG) + BCNU 40 mg/m² + radiation therapy (RT)
Study: 25407559
Drug: BCNU 200
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU 200 mg/m² + RT
Study: 24267123
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride 0.4 mg
Study: 24267123
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride 0.4 mg plus meloxicam 15 mg
Study: 15542510
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori testing plus eradication therapy
Study: 11583187
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus doxorubicin (A) combination therapy
Study: 28449631
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 µg/kg followed by 0.5 µg/kg/h until abdominal closure
Study: 25863753
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with 30 Gy to the site of residual disease
Study: 20024718
Drug: Self-selected treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected treatment partners
Study: 20024718
Drug: Community-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based treatment partners
Study: 20024718
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment partner
Study: 17067318
Drug: Bimosiamose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimosiamose disodium (2-140 mg single dose, 8-70 mg twice daily)
Study: 17067318
Drug: Bimosiamose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimosiamose disodium (doses > or =50 mg given twice daily and 105 mg once daily)
Study: 15325680
Drug: High wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High wheat bran fiber (WBF) supplementation (13.5 g/d)
Study: 15325680
Drug: Low wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low wheat bran fiber (WBF) supplementation (2 g/d)
Study: 26942345
Drug: Investigational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational group B streptococcal vaccine
Study: 16645152
Drug: Oral E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2/NETA (1 mg/0.5 mg)
Study: 16645152
Drug: Intranasal E2/NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2/NET
Study: 17317046
Drug: Oral E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2/NETA
Study: 6385878
Drug: ticarcillin 3
Normalized name: ticarcillin 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticarcillin 3 grams every 4 hours and tobramycin 1.5 mg/kg every 8 hours
Study: 25955866
Drug: DEX infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX infusion at 0.5 μg/kg/h for 10 min and then adjusted to 0.2 to 0.5 μg/kg/h
Study: 25955866
Drug: DEX infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX infusion
Study: 11956353
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusion
Study: 22202972
Drug: Daikenchuto (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT) 7.5 g/day from the day after surgery until the 7th postoperative day
Study: 16296572
Drug: nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5 mg once daily
Study: 16296572
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg once daily
Study: 12063454
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g before skin incision, 400 mg/h during operation, and 500 mg in pump priming)
Study: 8582464
Drug: Hamamelis distillate
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamamelis distillate cream (5.35 g hamamelis distillate with 0.64 mg ketone/100 g)
Study: 10397661
Drug: Drug-free vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free vehicle
Study: 27205
Drug: Orciprenaline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orciprenaline (1.5 mg)
Study: 31995130
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication in combination with cognitive behavioral therapy
Study: 30935866
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment of LHRH-a)
Study: 22226275
Drug: Pancreatic polypeptide
Normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic polypeptide (PP) infusion at 2 pmol/kg/min for 72 hours
Study: 22226275
Drug: Pancreatic polypeptide
Normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic polypeptide (PP) infusion
Study: 19687024
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (GA and IFNbeta1b)
Study: 15579335
Drug: Quadrivalent vaccine
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent vaccine (Rispoval 4)
Study: 11499722
Drug: PVS-guided antiarrhythmic
Normalized name: PV
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVS-guided antiarrhythmic drug therapy (n = 142)
Study: 11499722
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic therapy (controls, n = 353)
Study: 11499722
Drug: Propafenone (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (specific agent)
Study: 7995387
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via p‐MDI (0.25 mg)
Study: 7995387
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via Turbuhaler (0.25 mg)
Study: 2892739
Drug: Indomethacin suppositories
Normalized name: Indomethacin Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppositories (2 X 100 mg)
Study: 30974501
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion threshold (Hb < 75 g L‐1)
Study: 30974501
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion threshold (Hb < 95 g L‐1 in intensive care and < 85 g L‐1 outside intensive care)
Study: 23925396
Drug: Vaginal sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal sildenafil citrate (100 mg single dose)
Study: 19309415
Drug: Clonidine (CLO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (CLO), 0.1 mg or 0.15 mg b.i.d., for 6 days
Study: 17372257
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in fasting insulin by 1 microunit/mL
Study: 17372257
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with >39% body fat and >4.5 microunits/mL insulin levels
Study: 17372257
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in body fat percentage or insulin over time
Study: 13129740
Drug: Valsartan therapy
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan therapy for 8 weeks
Study: 9185432
Drug: PCA+BI (Patient-Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA+BI (Patient-Controlled Analgesia with nighttime morphine infusion)
Study: 8267401
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and postoperative chemotherapy (treatment A) [5-drug combination chemotherapy + tamoxifen]
Study: 8267401
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and postoperative radiotherapy (treatment B)
Study: 8267401
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to chemotherapy (treatment A)
Study: 8267401
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to chemotherapy (treatment A)
Study: 3790404
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (SRT) administered under fasting conditions
Study: 3790404
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (SRT) administered after a standardised breakfast
Study: 3790404
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (SRT) administered under fasting conditions in the evening (adults only)
Study: 3790404
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline as a reference
Study: 26676203
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants placed in fresh sockets associated with chronic periapical disease (test group)
Study: 24512981
Drug: Trabectedin 1.5mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.5mg/m2 24‐h intravenous infusion every 3 weeks (Arm A)